The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
Alzheimer’s has no cure and can’t be reversed, but the FDA-approved drug can slow cognitive decline. Eli Lilly reported that ...
Now, there’s a new perk to consider: It may help lower your risk of cognitive decline and potentially dementia. That’s the ...
“This follows a Type C meeting with the FDA where the Agency stated that it was open to considering the accelerated approval ...
Silo is currently conducting a GLP-compliant pharmacokinetic and pharmacodynamic studies and recently submitted a pre-IND briefing package and meeting request to the U.S. Food and Drug Administration ...
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market continues to demonstrate strong performance, ...
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...
It was a regular week for the biotech sector with quite a few important pipeline and regulatory updates. Among these, Cassava ...
Blue-chip stocks are considered to be the most reliable stocks in the industry. Whether you are a beginner or a professional ...
Cuban's Cost Plus Drug Company is working with the FDA to import and distribute penicillin temporarily to offset the shortage of Pfizer supplies. Humana, Ardent Health, Novartis, and more are also in ...
"Earlier pre-clinical testing by CRE showed positive results from the PUFA analogs in slowing or reversing several neurodegenerative disease processes in Alzheimer's ... Drug User Fee Act (PDUFA) ...